Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI)

https://www.scinai.com

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on development and manufacturing of products for the prevention of infectious diseases. The Company had been developing M-001, a novel flu vaccine candidate that was designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza. In seven Phase 1/2 and Phase 2 clinical trials designed to test for immunogenicity, the Company was able to demonstrate M-001 was effective in stimulating an immune response to a broad range of flu strains. In October 2020, the Company completed a Phase 3 clinical trial of M-001 which failed to meet the trial’s primary and secondary efficacy endpoints. The company is now pursuing opportunities in the infectious disease space, including exploring several alternatives for development of a pipeline of assets. *

	Start	2023-09-06 renamed
	Predecessor	BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV)
	Industry	VHH antibody technology (Llama-derived antibody technology)
	Industry 2	immunotherapy
	Person	Reichman, Amir (BiondVax 202103– CEO before GSK Vaccines + Novartis Vaccines + NeuroDerm)
	Person 2	Halpert, Liat (Scinai Immunotherapeutics 202402– Head of BusDev + Sales before 14 years at Novartis)

	Region	Jerusalem
	Country	Israel
	Street	Hadassah Ein Kerem Campus Jerusalem BioPark
	City	n. a. Jerusalem
	Tel	+972-8-930-2529
		Address record changed: 2023-09-23

Basic data	Employees	n. a.
	Currency	USD
	Profit	-9,966,000 (2017-12-31)
	Cash	7,200,000 (2020-09-30)

		* Document for »About Section«: BiondVax Pharmaceuticals Ltd.. (1/21/21). "Press Release: BiondVax Announces Appointment of Amir Reichman as New CEO". Jerusalem.

		Record changed: 2024-08-24